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BACKGROUND
The heart failure population is ever expanding, with approximately 23 million people worldwide diagnosed with heart failure (HF). In the United States, acute HF (AHF) accounts for more than 1 million hospital admissions. [1] [2] [3] Despite improvements in morbidity and mortality for patients with chronic HF with reduced ejection fraction (EF) due to pharmacological and device-based therapies, rates of admission, readmission, and mortality remain high. Overall, in-hospital mortality is relatively low; it is the early postdischarge period, termed the "vulnerable phase" (VP), where the greatest number of adverse outcomes occurs ( Figure 1 ).
The VP begins with an AHF exacerbation and lasts up to 6 months postdischarge. Patients who survive this 6-month period after AHF represent a uniform cohort without significant variability among clinical profiles or systolic blood pressure classifications at the time of admission, thus suggesting an end point for the VP. 4 This VP period is associated with an increased risk of readmission and mortality, with rates of 30% and 10%, respectively, within the first few weeks. 5 Such poor outcomes may be attributed to cardiac factors (such as myocardial infarctions, atrial fibrillation, and uncontrolled hypertension), noncardiac comorbidities (such as diabetes, chronic obstructive pulmonary disease, and infection), patient-related factors (medication nonadherence, alcohol and substance abuse, dietary indiscretions), and system-based factors (such as poor access to discharge follow up). 6 Additionally, the VP can be further categorized into 3 overlapping subphases: early, middle, and late phases. The very early VP includes the acute exacerbation and lasts upto the first few days after discharge. This was evident in the European Society of Cardiology Heart Failure Long-Term registry where 49% of patients admitted in cardiogenic shock died within the first 24 hours following presentation, illustrating the importance of early identification of hypoperfusion and appropriate in-hospital triage of these high risk patients. 4 The early VP begins at the moment of discharge, and readmissions during this time frame have been attributed to both patient-and system-related factors. The later VP takes into account all precipitating factors and comorbidities within 6 months of discharge 7 (Table 1) . As time progresses following a AHF, the readmission and mortality rates gradually decline, as highlighted in the Candesartan in Heart Failure: Assessment of Reduction on Mortality and Morbidity trial. Odds for mortality declined from 6-fold during the first month after discharge to 2-fold over the time of the trial. 8 The susceptibility of patients during the VP presents a potential opportunity to improve patient outcomes by altering the trajectory of an otherwise poor prognosis. 9 be attributed to numerous contributing factors, including the short-term worsening of hemodynamics attributed to a failure to relieve congestion during the index hospitalization, with progressively increased left ventricular (LV) filling pressures. 10, 11 This elevation of LV pressure ultimately leads to persistent hemodynamic congestion and long-term persistent multiorgan injury reflected in abnormalities in markers, including troponin and creatinine.
Often, it is the signs and symptoms associated with congestion that ultimately lead to HF admissions and subsequent readmissions. [12] [13] [14] During AHF, intravenous diuretics are employed with the goal of lowering elevated filling pressures. Over the course of the hospitalization, there is a resolution of symptomatic congestion. 5 However, approximately 20% of patients are discharged despite persistent signs and symptoms of HF. 4 A negligible decrease or an increase in body weight suggests a possible failure to relieve clinical congestion during index hospitalization, which may potentially contribute to the high postdischarge event rate in the European Society of Cardiology Heart Failure Long-Term registry. 4 In the Romanian AHF Syndrome registry, regardless of age, gender, and LVEF, 83% of AHF patients reported their status to be improved at discharge. 15 However, despite symptomatic improvement, there often remains persistent hemodynamic, subclinical congestion at the time of discharge. 5 Given the poor hemodynamic reserve commonly seen following a HF exacerbation, the AHF patient population is exquisitely sensitive to changes in LV filling pressures with even the most modest increase potentially leading to worsening of symptoms, worsening multiorgan failure, and readmission. 10, 11 This cycle of admission and readmission ultimately predisposes patients to worse outcomes with poor prognosis and an increased risk of morbidity and mortality. 16 AHF patients often are burdened with numerous comorbidities that contribute to early postdischarge event rates and predispose this population to AHF during the VP. Addressing both cardiac and noncardiac comorbidities is vital in preventing decompensation during the VP; approximately 40% of deaths and readmissions within 60 days of AHF were secondary to noncardiovascular causes. 12 The current culture of medicine, where system-based failures predisposes patients to delayed care, contributes to the worsening of outcomes during the VP. The inappropriate triage of critically ill and complex patients during the very early VP, to hospital facilities or care settings poorly equipped to manage them, leaves the patient at the risk for worse outcomes compared with those who initiated their care at facilities equipped to handle high-acuity patients. 4 The lack of a comprehensive discharge plan, via difficulty arranging immediate outpatient follow-up, lack of resources to pay for medications, follow-up, and transportation, or poor medical education, leaves this population vulnerable for deterioration and rehospitalization.
DATA SOURCES

Identification of patients at highest risk
Although the VP following AHF is marked by high risk for postdischarge events, there are certain subgroups of patients at higher risk than others. 17, 18 The identification of these high-risk groups with the use of emerging prognostic biomarkers and risk-stratifying tools may allow for targeted treatment of higher risk patients during hospitalization or immediate postdischarge period (Table 2) . Natriuretic peptides (NPs) levels are among the most powerful postdischarge risk stratification markers in HF. 19, 20 Serial measurements of NP may help identify patients at the high risk for decompensation during the VP, especially during the transition from hospitalization to early outpatient follow-up. 21 Greene et al 22 analyzed both baseline and 30 days postdischarge levels of NTproBNP in the Aliskiren Trial in Acute Heart Failure Outcomes (ASTRONAUT) cohort and found that an increased trajectory in NT-proBNP was independently associated with cardiovascular mortality (CVM) and AHF [hazard ratio (HR), 1.14; 95% confidence interval FIGURE 1. U-shaped distribution of readmission associated with HF management. Rehospitalization risk among patients hospitalized for HF. Among patients who have repeat hospitalization for HF or other cardiovascularrelated disease, a 3-phase lifetime readmission risk exists. Red indicates period of highest risk for readmission immediately after discharge and just before death. White indicates the lower-risk chronic phase where the rate of readmission levels off before end of life.
Vulnerable Phase of HF e457 23 However, the Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) study, which followed 894 patients with HF and a reduced ejection fraction (HFrEF), found that the use of NT-proBNP was not useful in predicting the time-to-first AHF or CVM in this population (HR, 0.98; 95% CI, 0.79-1.22; P 5 0.88). 24 The fact that the control arm underwent more frequent outpatient visits per year compared with what typically occurs in standard practice suggests that more frequent outpatient follow-up above usual care improves outcomes. This does not imply that guided biomarker therapy is better; rather, perhaps, more frequent follow-up of patients is needed. During AHF, a significant number of patients have elevations in troponin secondary to myocardial injury outside of an acute coronary syndrome. The elevation in troponin levels has been associated with worsening HF exacerbation, more severe symptoms, greater needs for aggressive supportive measures, and worse overall outcomes. 25 Analysis of the ASTRONAUT cohort found that troponin elevations at the 30-day postdischarge mark were associated with increased all-cause mortality (ACM) (HR, 1.59; 95% CI, 1.18-2.13) and CVM/AHF (HR, 1.28; 95% CI, 1.03-1.58) at 12 months. Assessing troponin levels postdischarge identifies patients with long-term persistence of myocardial injury; such patients are at the highest risk for readmission and may serve as a complement to NP levels in risk stratification. 26 Activation of the renin-angiotensin-aldosterone system in response to decreased renal blood flow leads to a compensatory mechanism aimed at augmenting the inadequate arterial pressure. Consequently, there are often fluctuations in blood urea nitrogen (BUN) levels during AHF, reflecting both congestion and fluid retention. 27 Fluctuations in BUN levels during AHF have been investigated by numerous trials. Two retrospective analysis suggested BUN could serve as a marker of neurohormonal activation even in the presence of renal dysfunction. 28, 29 In 171 patients admitted with AHF, there was a rise in BUN independent of basal renal dysfunction, thus pointing to the activation of RAAS as the inciting event. 29 As with the previous markers, decreases in BUN without resolution of clinical congestion were not associated with improved outcomes.
Another potential surrogate marker for assessing the underlying risk of AHF patients is serum osmolality. In a post hoc analysis of the EVEREST trial, lower discharge serum osmolality was predictive of higher ACM (HR, 1.61; 95% CI, 1.19-1.75) and those patients at the lower spectrum of osmolality demonstrated many features of advanced HF. This marker may represent a marker of residual congestion beyond currently available parameters, including serum sodium and NPs. 30 In addition to markers of risk, numerous risk stratification tools have been developed to aid in the identification of patients at highest risk based on their position on the VP time line. During the earlier portion of the VP, both the Acute Decompensated Heart Failure National Registry risk tree and the Improving Heart Failure Risk Stratification in the ED tool may be used to stratify risk. 13, 31 Once patients progress to the early VP, the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy risk score and the Center for Outcome Research and Evaluation online readmission risk calculator for HF can help identify patients at the risk for poor outcomes within 7 days of discharge and the 30-day all-cause readmission rates, respectively. The Get With the Guidelines-Heart Failure (GWTG-HF) risk score aids in stratifying patients during the late subphase of VP and predicts ACM for future AHF.
POTENTIAL SOLUTIONS
Optimizing management
Despite being able to identify markers predictive of worse outcomes, the greatest threat to AHF patients is the risk of readmission secondary to persistent congestion. 3, 32, 34 The primary focus during an AHF hospitalization must be the achievement of both clinical and subclinical decongestion. This can only be accomplished by identifying those patients with persistent congestion despite clinical improvement. Thus, the assessment and grading of congestion before hospital discharge remains a crucial opportunity to treat patients who have yet to reach optimal euvolemia. 33 
Pharmacologic therapies
Once optimal decongestion has been achieved .
Despite the challenge associated with the management of HF with preserved EF due to the lack of lifesaving therapies, a wide spectrum of medications has been shown to reduce mortality in those patients with HFrEF. These medications include beta-blockers, angiotensinconverting enzyme (ACE) inhibitors, aldosterone receptor blockers (ARBs), aldosterone antagonists, and angiotensin receptor-neprilysin inhibitors. Yet despite their proven clinical efficacy, the initiation and uptitration of these medications remains suboptimal. Analysis of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure registry revealed that fewer than 10% of the patients were at target beta-blocker doses upon discharge with the average beta-blocker dose being less than 50% of the target dose. 34, 35 Further compounding the problem was the failure to uptitrate medications within 90 days of postdischarge. Numerous studies, including the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), Systolic Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT), and Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD) trials, have demonstrated the overall suboptimal dosing of betablockers upon discharge. [36] [37] [38] With regards to ACE inhibitors and ARBs, hyperkalemia and renal dysfunction remain the major concerns leading to underutilization, with nearly 20% of the eligible HFrEF patients not receiving ACE inhibitors or ARBs. 39 The utilization of mineralocorticoid receptor antagonists is equally poor, with less than one-third of eligible patients receiving prescriptions at discharge. 40, 41 Similarly, in the subset of African American population with HF intolerant of ACE inhibitors, the usage rate of hydralazine with isosorbide dinitrate remains below 25% despite evidence showing a mortality benefit in this population. 42, 43 Digoxin is another underutilized medical therapy that may improve outcomes. Although there is no mortality benefit associated with its use, digoxin decreases HF hospitalization by 28%. 44 Furthermore, in high-risk patients, defined as New York Heart Association class III-IV symptoms, with LVEF of ,25% or cardiothoracic ratio of .55%, digoxin has also been showed to reduce the composite of ACM or hospitalization, whereas withdrawing digoxin therapy leads to an increased risk of HF. 45, 46 Use of digoxin remains controversial however.
The index hospitalization provides an opportune time for both the initiation and appropriate uptitration of guideline-directed medical therapy in a monitored setting. Studies have indicated that initiation and aggressive uptitration of medications before discharge were associated with a significant reduction in the adjusted risk of death and rehospitalization. This was seen in the analysis of beta-blocker usage in eligible patients within the OPTIMIZE-HF trial cohort. 47 Additionally, an analysis of the metabolic exercise test data combined with cardiac and kidney indexes score database suggests that higher dose of beta-blockers were associated with an overall better prognosis compared with those on medium and low doses. 48 The GWTG-HF registry revealed that patients who were continued or newly started on medication before discharge had a significantly improved thirty-day mortality in comparison to those not started on therapy, with 1-year mortality of 28.2% for patients continued and 29.7% for patients started on ACEi/ARB compared with 41.6% for patients discontinued and 41.7% for patients not started on therapy. 49 
DEVICE THERAPIES
Patients with severe HF must be evaluated for implantable cardiac defibrillators (ICDs) or cardiac resynchronization therapy before discharge. Although the Danish Study to Assess the Efficiency of ICDs in Patients With Non-ischemic Systolic Heart Failure on Mortality (DAN-ISH) study raises some questions regarding the use of ICDs in all HFrEF patients, ICD therapy remains an integral component in the care of HFrEF patients. 50, 51 Cardiac resynchronization therapy provides the added benefit of reverse remodeling, which in turn leads to reductions in cardiac volumes, improvements in EFs, and subsequently a reduction in HF events and mortality. 52, 53 NONPHARMACOLOGIC SYSTEM STRATEGIES Patient education, home-based monitoring (either by the patient or by a visiting nurse service), and close follow-up in multidisciplinary HF clinics are all additional strategies that serve to address systembased factors that potentiate readmissions following AHF. Close postdischarge follow-up within 1 week of discharge led to fewer readmissions at 30 days (risk-adjusted HR, 0.85; 95% CI, 0.78-093). 54 Additionally, a meta-analysis of transitional care services, such as follow-up with home-visiting programs, multidisciplinary HF clinics, and structured telephone support, revealed that these interventions result in a reduction in all-cause readmission and mortality at 3-6 months post discharge. 55 Home visiting programs resulted in a significant reduction in both mortality and readmissions (HR, 0.77 and 0.75, respectively), whereas multidisciplinary HF clinics had even higher reductions in mortality and readmissions at the 6-month mark (HR, 0.56 and 0.70, respectively). However, there are some conflicting data in regards to ideal or best transitional care management. Visiting nurse programs and increased surveillance via telemonitoring failed to demonstrate any significant improvement in outcomes. [56] [57] [58] [59] Observational data failed to consistently support an outcome benefit associated with dietary modifications toward a salt-restricted diet. In fact, in the setting of high diuretic doses, a normal sodium diet was shown to reduce rates of renal dysfunction and readmission when compared with a low-sodium diet. [60] [61] [62] There are inconsistent impacts on outcomes for other interventions, such as regular postdischarge telephone calls and the practice of alerting outpatient physicians to patient discharge. 63 
COMORBIDITY OPTIMIZATION
The AHF population frequently has significant cardiac (eg, atrial fibrillation, ischemia, valvular heart disease) and noncardiac (eg, diabetes mellitus, sleep disordered breathing, chronic lung disease, anemia, depression, chronic kidney disease) comorbidities that contribute substantially to early postdischarge event rates. These comorbid conditions and their management can directly and indirectly contribute to poor outcomes resulting in rehospitalization. Addressing these comorbidities is crucial to improving postdischarge outcomes, especially given that 40% of all deaths and rehospitalizations within 60 days following a HF hospitalization are due to noncardiovascular causes. 12 
POTENTIAL FUTURE OPTIONS: MOVING TO THE LEFT
Rather than waiting 1 to 3 months per inclusion criteria of SHIFT, EMPHASIS, and PARADIGM-HF trials, earlier initiation of novel therapies during the index hospitalization could potentially medically optimize patients and prevent future AHF. In addition, there are other novel therapies currently under investigation that might further reduce postdischarge risk among HF patients. These include ongoing clinical trials with novel agents, including a sodium glucose cotransporter 2 inhibitor, canagliflozin, a subcutaneous natriuretic peptide, omecamtiv mecarbil (GALACTIC-HF, NCT02929329), and a subcutaneous guanylate cyclase stimulator, vericiguat (VICTORIA, NCT02861534). [64] [65] [66] The Canagliflozin Cardiovascular Assessment Study found that in patients with type-2 diabetes mellitus at high risk for cardiovascular events, treatment with canagliflozin led to an overall reduction in cardiovascular events (HR, 0.86; 95% CI, 0.75-0.97) and AHF (HR, 0.67; 95% CI, 0.52-0.87). 67 The findings of the Cardiovascular Assessment Study trial can potentially lead to canagliflozin being included as an adjunct treatment for the large portion of the HF population with type-2 diabetes mellitus; however, these findings are yet to be incorporated into the ACC/AHA/Heart Failure Society of America guidelines for the management of HF. 68 Recently, the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure trial demonstrated omecamtiv's ability to improve cardiac output while simultaneously reducing ventricular diameter in patients with chronic HF. 65 These novel therapies may ultimately prove to be useful tools to help reduce readmissions and mortality in HF patients during this VP. Appropriate allocation of resources focused on close follow-up and preventative measures for those at the highest risk of readmission and mortality may also provide a unique, patient-centered opportunity to escort the AHF population through the vulnerable period and into a stable chronic HF status. 17, 18, 69, 70 
CONCLUSION
The VP following AHF is a critical period lasting 6 months after discharge, during which there is heightened risk for adverse outcomes. The risk for readmission begins and continues throughout hospitalization: Failure to adequately decongest patients and maximize proven guideline-directed medical therapy before discharge or soon after discharge increases the risk for adverse events. The identification of patients at risk of poor postdischarge outcomes and the resolution of both clinical and subclinical congestion remain the most imperative of goal before discharge following AHF. Once at decongestive state, proper implementation of HF therapies and close outpatient follow-up will bridge patients through the VP and into a stable, chronic HF status.
